STAT3 and lung cancer: Building on the concept of targeted gene silencing, cationic solid lipid nanoparticles containing plasmid DNA designed for STAT3 downregulation (cSLN/plasmid DNA complexes) were developed to deliver RNA interference molecules targeting STAT3 in resistant lung cancer cells.